{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T08:05:08Z","timestamp":1778659508374,"version":"3.51.4"},"reference-count":68,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2008,5,1]],"date-time":"2008-05-01T00:00:00Z","timestamp":1209600000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2008,5]]},"DOI":"10.1016\/j.blre.2008.02.001","type":"journal-article","created":{"date-parts":[[2008,3,15]],"date-time":"2008-03-15T14:55:19Z","timestamp":1205592919000},"page":"117-126","source":"Crossref","is-referenced-by-count":59,"title":["Management of viral hepatitis in hematologic malignancies"],"prefix":"10.1016","volume":"22","author":[{"given":"Roberto J.","family":"Firpi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David R.","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.blre.2008.02.001_bib1","unstructured":"Davis GL. Impact of HCV infection: Projections into the next century. 28[4], 390A. 1998. [abstract]. Hepatology 1998;28."},{"key":"10.1016\/j.blre.2008.02.001_bib2","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1056\/NEJM199712113372406","article-title":"Hepatitis B virus infection","volume":"337","author":"Lee","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2008.02.001_bib3","doi-asserted-by":"crossref","first-page":"S173","DOI":"10.1002\/hep.20956","article-title":"Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005","volume":"43","author":"Yim","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.blre.2008.02.001_bib4","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/S0168-8278(00)80134-8","article-title":"Occult hepatitis B virus after acute self-limited infection persisting for 30 years without sequence variation","volume":"33","author":"Blackberg","year":"2000","journal-title":"J Hepatol"},{"key":"10.1016\/j.blre.2008.02.001_bib5","first-page":"9","article-title":"Update on hepatitis B treatment","volume":"4","author":"Firpi","year":"2002","journal-title":"MedGenMed"},{"key":"10.1016\/j.blre.2008.02.001_bib6","doi-asserted-by":"crossref","unstructured":"de FR, Hadengue A, Lau G et al. EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002 Geneva, Switzerland. Consensus statement (long version). J.Hepatol. 2003;39 Suppl 1:S3-25.:S3\u201325.","DOI":"10.1016\/S0168-8278(03)00378-7"},{"key":"10.1016\/j.blre.2008.02.001_bib7","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/j.1600-0609.2006.00678.x","article-title":"Fulminant hepatitis after allogenic bone marrow transplantation caused by reactivation of hepatitis B virus with gene mutations in the core promotor region","volume":"77","author":"Kitano","year":"2006","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.blre.2008.02.001_bib8","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1111\/j.1445-5994.2007.01479.x","article-title":"Hepatitis B virus reactivation following immunosuppressive therapy: guidelines for prevention and management","volume":"37","author":"Lubel","year":"2007","journal-title":"Intern Med J"},{"key":"10.1016\/j.blre.2008.02.001_bib9","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1053\/j.gastro.2006.04.015","article-title":"Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy","volume":"131","author":"Hui","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.blre.2008.02.001_bib10","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/j.1365-2141.2006.06465.x","article-title":"Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies","volume":"136","author":"Lalazar","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2008.02.001_bib11","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/S0140-6736(77)91995-X","article-title":"Reactivation of hepatitis b after transplantation operations","volume":"1","author":"Nagington","year":"1977","journal-title":"Lancet"},{"key":"10.1016\/j.blre.2008.02.001_bib12","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1034\/j.1600-0609.2000.9l228.x","article-title":"Reactivation of hepatitis B virus infection in an anti-HBc and anti-HBs positive patient after allogeneic bone marrow transplantation","volume":"65","author":"Nordbo","year":"2000","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.blre.2008.02.001_bib13","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1002\/(SICI)1096-9071(200003)60:3<249::AID-JMV1>3.0.CO;2-C","article-title":"Hepatitis B virus reactivation in patients undergoing cytotoxic chemotherapy for solid tumours: precore\/core mutations may play an important role","volume":"60","author":"Steinberg","year":"2000","journal-title":"J Med Virol"},{"key":"10.1016\/j.blre.2008.02.001_bib14","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/rmv.322","article-title":"Hepatitis B virus (HBV) reactivation after cytotoxic or immunosuppressive therapy\u2013pathogenesis and management","volume":"11","author":"Xunrong","year":"2001","journal-title":"Rev Med Virol"},{"key":"10.1016\/j.blre.2008.02.001_bib15","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/1096-9071(200011)62:3<299::AID-JMV1>3.0.CO;2-0","article-title":"Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors","volume":"62","author":"Yeo","year":"2000","journal-title":"J Med Virol"},{"key":"10.1016\/j.blre.2008.02.001_bib16","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/hep.21051","article-title":"Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy","volume":"43","author":"Yeo","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.blre.2008.02.001_bib17","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.trim.2004.10.001","article-title":"Risk factors for cytomegalovirus, hepatitis B and C virus reactivation after bone marrow transplantation","volume":"13","author":"Zekri","year":"2004","journal-title":"Transpl Immunol"},{"key":"10.1016\/j.blre.2008.02.001_bib18","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1038\/sj.bmt.1704457","article-title":"Reactivation of resolved hepatitis B virus infection after allogeneic haematopoietic stem cell transplantation","volume":"33","author":"Knoll","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.blre.2008.02.001_bib19","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1023\/A:1008234807768","article-title":"Hepatitis B virus carriers in the treatment of malignant lymphoma: an epidemiological study in Japan","volume":"8 Suppl 1","author":"Kumagai","year":"1997","journal-title":"Ann Oncol"},{"key":"10.1016\/j.blre.2008.02.001_bib20","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/0016-5085(91)90599-G","article-title":"Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study","volume":"100","author":"Lok","year":"1991","journal-title":"Gastroenterology"},{"key":"10.1016\/j.blre.2008.02.001_bib21","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1046\/j.1352-0504.2003.00467.x","article-title":"High hepatitis B virus (HBV) DNA viral load is an important risk factor for HBV reactivation in breast cancer patients undergoing cytotoxic chemotherapy","volume":"11","author":"Zhong","year":"2004","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.blre.2008.02.001_bib22","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1182\/blood-2005-02-0698","article-title":"A long-term follow-up study on hepatitis B surface antigen-positive patients undergoing allogeneic hematopoietic stem cell transplantation","volume":"106","author":"Hui","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.blre.2008.02.001_bib23","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1046\/j.1440-1746.1999.01961.x","article-title":"Case report: lamivudine therapy for submassive hepatic necrosis due to reactivation of hepatitis B following chemotherapy","volume":"14","author":"Maguire","year":"1999","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.blre.2008.02.001_bib24","first-page":"2925","article-title":"Reactivation of hepatitis B but not hepatitis C in patients with malignant lymphoma and immunosuppressive therapy. A prospective study in 305 patients","volume":"46","author":"Markovic","year":"1999","journal-title":"Hepatogastroenterology"},{"key":"10.1016\/j.blre.2008.02.001_bib25","first-page":"327","article-title":"Lamivudine for the prevention of hepatitis B virus reactivation during autologous stem cell transplantation. A case report","volume":"85","author":"Silvestri","year":"2000","journal-title":"Haematologica."},{"key":"10.1016\/j.blre.2008.02.001_bib26","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/sj.bmt.1700885","article-title":"Hepatitis B virus infection in allogeneic bone marrow transplantation","volume":"20","author":"Ustun","year":"1997","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.blre.2008.02.001_bib27","first-page":"500","article-title":"Exacerbation of hepatitis in hepatitis B carriers following chemotherapy for haematological malignancies","volume":"25","author":"Wong","year":"1996","journal-title":"Ann Acad Med Singapore"},{"key":"10.1016\/j.blre.2008.02.001_bib28","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/1096-8652(200007)64:3<233::AID-AJH21>3.0.CO;2-W","article-title":"Fludarabine and risk of hepatitis B virus reactivation in chronic lymphocytic leukemia","volume":"64","author":"Yagci","year":"2000","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2008.02.001_bib29","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/(SICI)1096-9071(199911)59:3<263::AID-JMV1>3.0.CO;2-X","article-title":"Lamivudine in the treatment of hepatitis B virus reactivation during cytotoxic chemotherapy","volume":"59","author":"Yeo","year":"1999","journal-title":"J Med Virol"},{"key":"10.1016\/j.blre.2008.02.001_bib30","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1053\/jhep.2002.35068","article-title":"Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation","volume":"36","author":"Lau","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.blre.2008.02.001_bib31","doi-asserted-by":"crossref","DOI":"10.1111\/j.1478-3231.2007.01618.x","article-title":"Lamivudine prophylaxis is effective in reducing hepatitis B reactivation and reactivation-related mortality in chemotherapy patients: a meta-analysis","author":"Martyak","year":"2007","journal-title":"Liver Int"},{"key":"10.1016\/j.blre.2008.02.001_bib32","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1200\/JCO.2004.05.161","article-title":"Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy","volume":"22","author":"Yeo","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2008.02.001_bib33","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/hep.21513","article-title":"Chronic hepatitis B","volume":"45","author":"Lok","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.blre.2008.02.001_bib34","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1002\/1097-0142(19940215)73:4<1143::AID-CNCR2820730404>3.0.CO;2-U","article-title":"Hepatitis B virus DNA in peripheral blood leukocytes. A comparison between hepatocellular carcinoma and other hepatitis B virus-related chronic liver diseases","volume":"73","author":"Leung","year":"1994","journal-title":"Cancer"},{"key":"10.1016\/j.blre.2008.02.001_bib35","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1097\/01.TP.0000151661.52601.FB","article-title":"Progressive disappearance of anti-hepatitis B surface antigen antibody and reverse seroconversion after allogeneic hematopoietic stem cell transplantation in patients with previous hepatitis B virus infection","volume":"79","author":"Onozawa","year":"2005","journal-title":"Transplantation"},{"key":"10.1016\/j.blre.2008.02.001_bib36","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1038\/sj.bmt.1702039","article-title":"Acute hepatitis B after autologous stem cell transplantation in a man previously infected by hepatitis B virus","volume":"24","author":"Senecal","year":"1999","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.blre.2008.02.001_bib37","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/sj.bmt.1702455","article-title":"Hepatitis B viremia in a patient with documented previous HBV immunity after autologous transplantation of highly purified PBSC","volume":"26","author":"Dreger","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.blre.2008.02.001_bib38","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/sj.bmt.1702093","article-title":"Fulminant hepatitis B following bone marrow transplantation in an HBsAg-negative, HBsAb-positive recipient; reactivation of dormant virus during the immunosuppressive period","volume":"25","author":"Iwai","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.blre.2008.02.001_bib39","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1097\/00007890-199809150-00012","article-title":"Reverse seroconversion of hepatitis B after allogeneic bone marrow transplantation: a retrospective study of 37 patients with pretransplant anti-HBs and anti-HBc","volume":"66","author":"Dhedin","year":"1998","journal-title":"Transplantation"},{"key":"10.1016\/j.blre.2008.02.001_bib40","first-page":"256","article-title":"Fatal hepatic failure caused by chemotherapy-induced reactivation of hepatitis B virus in a patient with hematologic malignancy","volume":"71","author":"Sekine","year":"2000","journal-title":"Int J Hematol"},{"key":"10.1016\/j.blre.2008.02.001_bib41","doi-asserted-by":"crossref","first-page":"274","DOI":"10.7326\/0003-4819-121-4-199408150-00007","article-title":"Fatal reactivation of precore mutant hepatitis B virus associated with fibrosing cholestatic hepatitis after bone marrow transplantation","volume":"121","author":"McIvor","year":"1994","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.blre.2008.02.001_bib42","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/j.1478-3231.2004.0964.x","article-title":"Hepatitis B virus reactivation in breast cancer patients undergoing cytotoxic chemotherapy and the role of preemptive lamivudine administration","volume":"24","author":"Dai","year":"2004","journal-title":"Liver Int"},{"key":"10.1016\/j.blre.2008.02.001_bib43","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1093\/jac\/dki114","article-title":"Lamivudine prophylaxis in HBV carriers with haemato-oncological malignancies who receive chemotherapy","volume":"55","author":"Idilman","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.blre.2008.02.001_bib44","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/hep.21024","article-title":"A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo-lipiodolization","volume":"43","author":"Jang","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.blre.2008.02.001_bib45","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1053\/j.gastro.2003.09.026","article-title":"Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy","volume":"125","author":"Lau","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.blre.2008.02.001_bib46","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1002\/cncr.21701","article-title":"Lamivudine prophylaxis reduces the incidence and severity of hepatitis in hepatitis B virus carriers who receive chemotherapy for lymphoma","volume":"106","author":"Li","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.blre.2008.02.001_bib47","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s10549-004-0725-1","article-title":"Use of lamivudine to prevent hepatitis B virus reactivation during chemotherapy in breast cancer patients","volume":"88","author":"Yeo","year":"2004","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.blre.2008.02.001_bib48","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1002\/hep.21783","article-title":"Hepatitis B prophylaxis in patients undergoing chemotherapy for lymphoma: a decision analysis model","volume":"46","author":"Saab","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.blre.2008.02.001_bib49","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.bbmt.2005.09.001","article-title":"Extended lamivudine therapy against hepatitis B virus infection in hematopoietic stem cell transplant recipients","volume":"12","author":"Hsiao","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.blre.2008.02.001_bib50","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1053\/gast.2000.8559","article-title":"Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group","volume":"119","author":"Liaw","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1016\/j.blre.2008.02.001_bib51","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1053\/j.gastro.2003.09.033","article-title":"Long-term safety of lamivudine treatment in patients with chronic hepatitis B","volume":"125","author":"Lok","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.blre.2008.02.001_bib52","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1056\/NEJM200501203520324","article-title":"Adefovir dipivoxil for chemotherapy-induced activation of hepatitis B virus infection","volume":"352","author":"Perez-Roldan","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2008.02.001_bib53","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.jcv.2005.10.009","article-title":"Adefovir added to lamivudine for hepatitis B recurrent infection in refractory B-cell chronic lymphocytic leukemia on prolonged therapy with Campath-1H","volume":"35","author":"Cortelezzi","year":"2006","journal-title":"J Clin Virol"},{"key":"10.1016\/j.blre.2008.02.001_bib54","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/sj.bmt.1705290","article-title":"Adefovir therapy for lamivudine escape and hepatitis B virus reactivation after reduced intensity conditioning allogeneic stem cell transplantation","volume":"37","author":"Fouillard","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.blre.2008.02.001_bib55","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1053\/j.gastro.2005.06.055","article-title":"A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients","volume":"129","author":"Chang","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.blre.2008.02.001_bib56","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1056\/NEJMoa042957","article-title":"Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B","volume":"352","author":"Hadziyannis","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2008.02.001_bib57","first-page":"7","article-title":"Chronic hepatitis C and liver transplantation","volume":"4","author":"Davis","year":"2004","journal-title":"Rev Gastroenterol Disord"},{"key":"10.1016\/j.blre.2008.02.001_bib58","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1097\/00007890-199911270-00010","article-title":"The role of hepatitis C and B virus infections as risk factors for severe liver complications following allogeneic BMT: a prospective study by the Infectious Disease Working Party of the European Blood and Marrow Transplantation Group","volume":"68","author":"Locasciulli","year":"1999","journal-title":"Transplantation"},{"key":"10.1016\/j.blre.2008.02.001_bib59","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1182\/blood-2003-06-2145","article-title":"Long-term outcome of hepatitis C infection after bone marrow transplantation","volume":"103","author":"Peffault","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.blre.2008.02.001_bib60","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1038\/sj.bmt.1704519","article-title":"Hepatitis C virus in long-term bone marrow transplant survivors","volume":"33","author":"Ivantes","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.blre.2008.02.001_bib61","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1002\/hep.510290609","article-title":"Hepatitis C virus infection and bone marrow transplantation: a cohort study with 10-year follow-up","volume":"29","author":"Strasser","year":"1999","journal-title":"Hepatology"},{"key":"10.1016\/j.blre.2008.02.001_bib62","doi-asserted-by":"crossref","first-page":"3259","DOI":"10.1182\/blood.V93.10.3259.410k13_3259_3266","article-title":"Cirrhosis of the liver in long-term marrow transplant survivors","volume":"93","author":"Strasser","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.blre.2008.02.001_bib63","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1002\/(SICI)1097-0142(19980915)83:6<1224::AID-CNCR23>3.0.CO;2-6","article-title":"Liver dysfunction in patients infected with hepatitis C virus undergoing chemotherapy for hematologic malignancies","volume":"83","author":"Zuckerman","year":"1998","journal-title":"Cancer"},{"key":"10.1016\/j.blre.2008.02.001_bib64","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/sj.bmt.1700620","article-title":"Should people with hepatitis C virus infection receive a bone marrow transplant?","volume":"19","author":"Ribas","year":"1997","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.blre.2008.02.001_bib65","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1182\/blood.V83.7.1998.1998","article-title":"Hepatitis C virus infection is a risk factor for liver failure from veno-occlusive disease after bone marrow transplantation","volume":"83","author":"Frickhofen","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.blre.2008.02.001_bib66","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1097\/00043426-200303000-00002","article-title":"Hepatitis B and C infection in children undergoing chemotherapy or bone marrow transplantation","volume":"25","author":"Gigliotti","year":"2003","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1016\/j.blre.2008.02.001_bib67","article-title":"Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: update on defibrotide and other current investigational therapies","author":"Ho","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.blre.2008.02.001_bib68","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/sj.bmt.1705120","article-title":"Treatment of chronic hepatitis C virus in allogeneic bone marrow transplant recipients","volume":"36","author":"Peffault de","year":"2005","journal-title":"Bone Marrow Transplant"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X0800012X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X0800012X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T03:24:26Z","timestamp":1738121066000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X0800012X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,5]]},"references-count":68,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008,5]]}},"alternative-id":["S0268960X0800012X"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2008.02.001","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2008,5]]}}}